Original Articles
26 June 2025
Early Access
Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
0
Views
0
Downloads
Authors
Objective. Drug survival rate and time are important to demonstrate the effectiveness of treatment in patients with axial spondyloarthritis (axSpA) in real life. Therefore, we aimed to evaluate drug survival rate and predictors of discontinuation of certolizumab and secukinumab in axSpA patients.
Methods. This single-center retrospective cohort study included patients treated with certolizumab (n=239) and secukinumab (n=64) among axSpA patients followed up at the rheumatology clinic. Clinical, laboratory, and imaging findings, treatment duration, and reasons for discontinuation were evaluated between April 2019 and December 2022. Drug survival rate and time were analyzed using Kaplan-Meier analysis, and predictive factors associated with drug discontinuation were analyzed using multivariable Cox regression analysis.
Results. At 12 months, drug retention rates were 76% in the secukinumab group and 73% in the certolizumab group. The overall retention rate was similar in both groups (p=0.641). The median survival time was 66.0 months in the secukinumab group versus 62.8 months in the certolizumab group. A comparison of the patients who discontinued certolizumab treatment with those who continued showed that patients who discontinued certolizumab treatment had a higher frequency of female sex, peripheral arthritis, and inflammatory bowel disease. Comparison of the patients who discontinued secukinumab treatment with those who continued revealed that patients who discontinued secukinumab treatment only had a higher frequency of male sex. Multivariable Cox regression showed that male sex was independently associated with a lower risk of certolizumab discontinuation [hazard ratio (HR): 0.634, 95% confidence interval (CI): 0.41-0.97, p=0.036] and with a higher risk of secukinumab discontinuation (HR: 2.77, 95% CI: 1.18-6.49, p=0.018).
Conclusions. Our data showed that the drug survival rate of certolizumab and secukinumab was similar in patients with AxSpA. There was a lower risk of certolizumab discontinuation and a higher risk of secukinumab discontinuation in males.
Altmetrics
Downloads
Download data is not yet available.
Citations
Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377: 2127-37. DOI: https://doi.org/10.1016/S0140-6736(11)60071-8
Quilis N, Sivera F, Seoane-Mato D, Antón-Pagés F, Añez G, Medina F, et al. Prevalence of ankylosing spondylitis in Spain: EPISER2016 Study. Scand J Rheumatol 2020; 49: 210-3. DOI: https://doi.org/10.1080/03009742.2019.1669704
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res 2019; 71: 1285-99. DOI: https://doi.org/10.1002/acr.24025
Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewé RBM, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 2023; 82: 130-41. DOI: https://doi.org/10.1136/ard-2022-223298
Ceribelli A, Motta F, Vecellio M, Isailovic N, Ciccia F, Selmi C. Clinical trials supporting the role of the IL-17/IL-23 axis in axial spondyloarthritis. Front Immunol 2021; 12: 622770. DOI: https://doi.org/10.3389/fimmu.2021.622770
McInnes IB, Szekanecz Z, McGonagle D, Maksymowych WP, Pfeil A, Lippe R, et al. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology 2022; 61: 1783-94. DOI: https://doi.org/10.1093/rheumatology/keab740
Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol 2021; 73: 110-20. DOI: https://doi.org/10.1002/art.41477
van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology 2017; 56: 1498-509. DOI: https://doi.org/10.1093/rheumatology/kex174
Min HK, Kim HR, Lee SH, Hong YS, Kim MY, Park SH, et al. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure. Rheumatology 2021; 60: 5743-52. DOI: https://doi.org/10.1093/rheumatology/keab245
Michelsen B, Lindström U, Codreanu C, Ciurea A, Zavada J, Loft AG, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open 2020; 6: e001280. DOI: https://doi.org/10.1136/rmdopen-2020-001280
Min HK, Kim HR, Lee SH, Hong YS, Kim MY, Park SH, et al. Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis. Mod Rheumatol 2023; 33: 194-201. DOI: https://doi.org/10.1093/mr/roac005
Micheroli R, Tellenbach C, Scherer A, Bürki K, Niederman K, Nissen MJ, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2020; 79: 1203-9. DOI: https://doi.org/10.1136/annrheumdis-2019-215934
Glintborg B, Lindström U, Giuseppe DD, Provan SA, Gudbjornsson B, Hetland ML, et al. Danish Rheumatology Database (DANBIO), Anti-Rheumatic Therapy in Sweden/Swedish Rheumatology Quality (ARTIS/SRQ), Center for Rheumatology Research (ICEBIO), Finnish Register of Biological Treatment (ROB-FIN), and Norwegian Antirheumatic Drug Register (NOR-DMARD) registries. One-year treatment outcomes of secukinumab versus Tumor Necrosis Factor Inhibitors in spondyloarthritis: results from five nordic biologic registries including more than 10,000 treatment courses. Arthritis Care Res 2022; 74: 748-58. DOI: https://doi.org/10.1002/acr.24523
Rubbert-Roth A, Atzeni F, Masala IF, Caporali R, Montecucco C, Sarzi-Puttini P. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: are they the same? Autoimmun Rev 2018; 17: 24-28. DOI: https://doi.org/10.1016/j.autrev.2017.11.005
Green LJ, Yamauchi PS, Kircik LH. Comparison of the safety and efficacy of tumor necrosis factor inhibitors and interleukin-17 inhibitors in patients with psoriasis. J Drugs Dermatol 2019; 18: 776-88.
Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 2018; 29: 13-8. DOI: https://doi.org/10.1080/09546634.2017.1329511
Armağan B, Kılıç L, Farisoğulları B, Yardımcı GK, Bilgin E, Bölek EÇ, et al. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis. Rheumatol Int. 2023; 43: 147-56. DOI: https://doi.org/10.1007/s00296-022-05213-1
Gentileschi S, Rigante D, Sota J, Lopalco G, Giannotta MG, Emmi G, et al. Long-term effectiveness of secukinumab in patients with axial spondyloarthritis. Mediators Inflamm 2020; 2020: 6983272. DOI: https://doi.org/10.1155/2020/6983272
García-Dorta A, León-Suarez P, Peña S, Hernández-Díaz M, Rodríguez-Lozano C, González-Dávila E, et al. Association of gender, diagnosis, and obesity with retention rate of secukinumab in spondyloarthropathies: results form a multicenter real-world study. Front Med 2022; 8: 815881. DOI: https://doi.org/10.3389/fmed.2021.815881
Bilgin E, Farisoğulları B, Armağan B, Sarı A, Yardımcı GK, Bölek EÇ, et al. Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: real-life results from the HURBIO registry. Clin Exp Rheumatol 2020; 38: 609-14.
Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L, et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther 2020; 20: 813-21. DOI: https://doi.org/10.1080/14712598.2020.1761957
Alonso S, Villa I, Fernández S, Martín JL, Charca L, Pino M, et al. Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in Cantabria and ASTURias Study. Front Med 2021; 8: 679009. DOI: https://doi.org/10.3389/fmed.2021.679009
Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94. DOI: https://doi.org/10.1186/ar3369
Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69: 2002-8. DOI: https://doi.org/10.1136/ard.2009.124446
Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 2010; 62: 1362-9. DOI: https://doi.org/10.1002/acr.20258
Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, et al. The sex influence on response to Tumor Necrosis Factor-α inhibitors and remission in axial spondyloarthritis. J Rheumatol 2018; 45: 195-201. DOI: https://doi.org/10.3899/jrheum.17666
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: CD011535. Update in: Cochrane Database Syst Rev 2021; 4: CD011535. DOI: https://doi.org/10.1002/14651858.CD011535.pub4
Adami G, Idolazzi L, Benini C, Fracassi E, Carletto A, Viapiana O, et al. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement. Reumatismo 2023; 75: 28-34. DOI: https://doi.org/10.4081/reumatismo.2023.1559
Ramonda R, Lorenzin M, Chimenti MS, D'Angelo S, Marchesoni A, Selmi C, et al. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis. Front Immunol 2024; 15: 1435599. DOI: https://doi.org/10.3389/fimmu.2024.1435599
Christiansen SN, Horskjær Rasmussen S, Ostergaard M, Pons M, Michelsen B, et al. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study. RMD Open 2024; 10: e004166. DOI: https://doi.org/10.1136/rmdopen-2024-004166
Ethics Approval
This study was approved by our hospital's ethics committee (Reference number: E1-22-2826).How to Cite
Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab. (2025). Reumatismo. https://doi.org/10.4081/reumatismo.2025.1792
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
